Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Approximately half of all patients with non–small-cell lung cancer (NSCLC) develop brain metastases (BM) during the course of their disease, leading to significant challenges in treatment. Molecular targeted tyrosine kinase inhibitors have proven effective for patients with activating mutations in t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2015-09, Vol.10 (9), p.1268-1278
Main Authors: Baik, Christina S., Chamberlain, Marc C., Chow, Laura Q.
Format: Article
Language:English
Subjects:
Anaplastic lymphoma kinase
Brain metastases
Brain Neoplasms - genetics
Brain Neoplasms - secondary
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Epidermal growth factor receptor
Humans
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Non–small-cell lung cancer
Receptor Protein-Tyrosine Kinases - genetics
Receptor, Epidermal Growth Factor - genetics
Receptor, Epidermal Growth Factor - metabolism
Targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Approximately half of all patients with non–small-cell lung cancer (NSCLC) develop brain metastases (BM) during the course of their disease, leading to significant challenges in treatment. Molecular targeted tyrosine kinase inhibitors have proven effective for patients with activating mutations in the epidermal growth factor receptor gene and chromosomal rearrangements involving the anaplastic lymphoma kinase gene. Despite their efficacy in systemic disease control, their effectiveness in patients with BM is not well established. In this article, we review recent data on the use of epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors for treatment of patients with NSCLC and BM. These data highlight the potential for meaningful disease control within the central nervous system and the inherent challenges in treating patients with NSCLC and BM.
ISSN:1556-0864
1556-1380
DOI:10.1097/JTO.0000000000000615